Overview

Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb
R-Pharm

Treatments:

Epothilones
Taxane